{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-019508","form_type":"8-K","ticker":"NXGL","cik":"0001468929","company_name":"NEXGEL, INC.","filed_at":"2025-07-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.051032+00:00","generated_at":"2026-05-18T06:38:23.189083+00:00","sec_items":["7.01","2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"NEXGEL expands partnership with STADA; gets $1M non-dilutive capital for N.A. launches","bullets":["Expansion includes digestive enzyme formulas and scar/stretch mark solutions for North America.","STADA will advance $1 million in non-dilutive capital to support product launches and marketing.","Partnership builds on existing relationship; targets consumer health market in North America.","CEO Adam Levy cites shared opportunity and acceleration of go-to-market strategy."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-019508","json":"https://secwatch.observer/filing/0001641172-25-019508.json","markdown":"https://secwatch.observer/filing/0001641172-25-019508.md","text":"https://secwatch.observer/filing/0001641172-25-019508.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1468929/000164117225019508/0001641172-25-019508-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1468929/000164117225019508/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T06:38:23.189083+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}